EyePoint Pharmaceuticals, Inc. (EYPT) NASDAQ

14.01

+0.0015(+0.01%)

Updated at September 08 03:05PM

Currency In USD

EyePoint Pharmaceuticals, Inc.

Address

480 Pleasant Street

Watertown, MA 02472

United States of America

Phone

617 926 5000

Sector

Healthcare

Industry

Biotechnology

Employees

165

First IPO Date

January 27, 2005

Key Executives

NameTitlePayYear Born
Dr. Anna KluczewskaChief Executive Officer of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd164,457N/A
Dr. Jay S. Duker M.D.President, Chief Executive Officer & Director1.19M1959
Mr. David Scott Jones M.A.Senior Vice President & Chief Commercial Officer672,0841967
Dr. Ramiro Ribeiro M.D., Ph.D.Chief Medical Officer742,5781983
Mr. George O. Elston CPAExecutive Vice President & Chief Financial Officer824,4741965
Ms. Jennifer LeonardChief People Officer & Senior Vice President of IT0N/A
Dr. Marcia Sellos-Moura Ph.D.Senior Vice President and Head of Development & Program Management0N/A
Ms. Isabelle LefebvreChief Regulatory Officer0N/A
Mr. Michael J. MaciocioChief Manufacturing Officer0N/A
Mr. Ron I. Honig Esq.Chief Legal Officer & Company Secretary0N/A

Description

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.